Table 1.
Contraction frequency
| Drugs | Control (contract per 5 min) | 0–5 min | 25–30 min | n |
|---|---|---|---|---|
| DMSO 0.1% | 3.8 ± 0.8 | 4.1 ± 0.9 | 4.1 ± 0.7 | 6 |
| CPA (10 µM) | 4.0 ± 1.1 | 16.2 ± 3.4a | 6.8 ± 0.9 | 6 |
| 2-APB (10 µM) | 5.1 ± 1.2 | 4.1 ± 0.8 | 2.8 ± 0.5a | 7 |
| Caffeine (0.3 mM) | 4.5 ± 0.6 | 3.5 ± 1.1 | 3.2 ± 1.0 | 4 |
| CCCP (2 µM) | 4.5 ± 0.6 | 9.7 ± 1.7a | 3.7 ± 1.1 | 6 |
| Rotenone (1 µM) | 4.9 ± 0.7 | 6.2 ± 1.6 | 1.9 ± 0.4a | 7 |
| CGP37157 (10 µM) | 3.5 ± 0.5 | 2.2 ± 0.5a | 1.3 ± 0.6a | 7 |
| Kaempferol (10 µM) | 4.2 ± 0.6 | 3.6 ± 0.8 | 2.8 ± 0.8a | 5 |
| Oligomycin (3 µM) | 9.3 ± 1.5 | 9.8 ± 1.9 | 8.85 ± 0.6 | 3 |
Values are mean ± SEM.
a
significantly different from control P < 0.05 (Student's two-tailed paired t-test).
2-APB, 2-amino ethoxyphenylborate; CCCP, carbonylcyanide-3-chlorophenylhydrazone; CGP37157, 7-chloro-5-(2-chlorophenyl)-1,5-dihydro-4,1-benzothiazepin-2(3H)-one; CPA, cyclopiazonic acid; DMSO, dimethyl sulphoxide.